Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.40 |
| ▸ | MCHR2 | Q969V1 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL913917 | 0.99 | MCHR1 (0.40) | MCHR1KCNH2MCHR2HTR1ASLC2A1 | |
| SCHEMBL6963886 | 0.95 | SLC2A1 (0.38) | MCHR1KCNH2MCHR2HTR1ASLC2A1 | |
| Hydrochloric Acid SCHEMBL913670 | 0.94 | SLC2A1 (0.37) | MCHR1KCNH2MCHR2HTR1ASLC2A1 | |
| SCHEMBL6963120 | 0.93 | RHEB (0.38) | MCHR1KCNH2HTR1ASLC2A1 | |
| SCHEMBL915891 | 0.93 | KMT2A (0.38) | MCHR1KCNH2SLC2A1 | |
| Hydrochloric Acid SCHEMBL915070 | 0.92 | RHEB (0.38) | MCHR1KCNH2HTR1ASLC2A1 | |
| SCHEMBL914491 | 0.92 | MAOB (0.43) | MCHR1KCNH2SLC2A1ALDH1A1 | |
| SCHEMBL915183 | 0.92 | MCHR1 (0.38) | MCHR1KCNH2MCHR2SLC2A1CYP3A4 | |
| SCHEMBL12906112 | 0.92 | MCHR1 (0.38) | MCHR1KCNH2MCHR2SLC2A1CYP3A4 | |
| SCHEMBL6965058 | 0.92 | SLC2A1 (0.41) | MCHR1KCNH2MCHR2HTR1ASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | MCHR1 246/4885KCNH2 2554/4885MCHR2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.